Q3 2026 Humana Inc. Earnings Conference Call - HUMANA INC

Explicit Guidance:

• EPS: Full-year adjusted EPS outlook increased to at least $9.50 (up from $9) for 2026.
• Margins: On track to double individual MA pre-tax margin in 2026 (excluding STARS headwind); targeting 3%+ margin by 2028.
• Trend Rates: 2026 cost trends running at 7–8% (actuals lower end of range); 2027 cost trends expected to rise to 8–9% (driven by Part D 14–15% growth and slightly higher medical costs).
• Cost Structure: Managing cost structures assuming a sustainable "top quartile" Star rating baseline rather than "top decile."
• Capital Metrics: Expect a ~130 bps reduction in the GAAP debt-to-capital ratio in Q4 2026 due to the BlackRock JV; will no longer require funding a put option in 2027 that would have increased debt-to-cap by ~130 bps.
• Cash Flow/Dividends: Dividend payout ratio targeted to increase to a "more normalized level" once earnings power recovers; buybacks expected to increase to offset dilution.

Business-Segment Outlook:

• Medicare Advantage (MA): 2027 membership expected to grow (AEP performance ahead of plan; strong recapture of members from exited plans); product portfolio positioned to deliver necessary margin progression for 2028.
• Star Ratings (MA): 2026 BY28 member-weighted star rating achieved at 4.17 (well above top quartile goal); BY29 goal remains top quartile performance. BY28 performance expected to generate a "one-time tailwind" in 2028, portions of which will be used for reinvestment and the remainder passed to shareholders (quantification to follow late next year/2027).
• CenterWell: Added ~147,000 members in 2026 (30% growth) via organic growth and MaxHealth acquisition; operating costs in PCO under pressure in one Florida geography, but actions taken to ring-fence and mitigate.
• Medicaid: Footprint expanded to 13 states (11 active); 104,000 membership growth in 2026; new contracts pending in Georgia and Texas.
• Group MA: Underwent significant recontracting effort resulting in a 500 bps improvement in margins (excluding STARS headwind); full benefits expected to realize upon STARS recovery in 2028.

Market and Competitive Outlook:

• Competitive Dynamics: Seeing consolidation among smaller plans; major players are "better positioned than perhaps expected" given planned exits.
• Pricing & Product: Product positioning and pricing for margin are primary 2027 priorities; "pricing for margin" is the #1 focus, followed by retention, then growth.
• Distribution: Outperformance driven by improved quality of distribution/broker partners; retention data for 2027 not yet finalized but early signals positive.
• Reinsurance: Use of reinsurance in MA expected to remain stable in 2027 after optimization this year (reducing capital requirement from ~12% to <10% of premiums).

Macro / Industry Outlook:

• Health Tech: Part D trend significantly impacted by a robust health technology pipeline (pricing 14–15% increase into 2027 bids).
• Regulatory/Financial: No known macro headwinds for 2027 other than carrying the current STARS headwind; operating discipline ensures resilience against external volatility.

Strategic Initiatives:

• BlackRock JV: Closed new joint venture in 2026 replacing Welsh Carson JV; BlackRock has right to exit via sale; Humana has option to purchase clinics from JV starting in 2028; if full acquisition not met by 2033, BlackRock can purchase remaining clinics.
• Balance Sheet Optimization: Divestment of minority interest in Gentiva closing this quarter (~$900M pre-tax proceeds); JV structure reduces cost of capital and JV liabilities.
• Reinvestment: One-time BY28 STARS tailwind will fund one-time investments to solidify Star capabilities and improve customer experience/outcomes.
• Investor Update: Comprehensive "waterfall" update on 2027/2028 targets (including margin expansion, cost transformation, and Group MA improvements) scheduled for December 10th Investor Day.

Risks and Headwinds to Outlook:

• STARS Volatility: Future Star ratings (and resulting financial tailwinds) depend on competitor actions and the shrinking gap to top quartile targets over the next 15 months.
• Membership Mix: Final margin impact depends on 2027 membership size and composition (retention vs. new sales), which remains early in the AEP cycle.
• Capacity Constraints: Operational capacity limits will dictate the amount of STARS tailwind that can be productively invested.
• Geographic Pressure: Specific pressure in a Florida PCO geography (outlying facilities) though steps have been taken to address.
• Valuation Timing: Exact quantification of BY28 tailwind and its allocation (earnings vs. investment) will not be ready until late next year or 2027 Q4.

Management Tone on the Future:

• Confidence: High confidence; CEO describes position as "good place" with "execution is strong and improving" and strategy "moving from on plan towards being ahead of plan."
• Discipline: Emphasis on "discipline" over "conservatism" in managing cost structures and capital allocation; managing the business to a "minimum threshold" (top quartile) to ensure long-term viability.
• Forward-Looking: Positive sentiment regarding 2027 and 2028, citing momentum, "ahead of plan" execution, and the ability to make capital choices (dividends, M&A, buybacks) with a fortified balance sheet.

Miscellaneous:

• Timeline: BY28 (2026 ratings) impact realized in 2028 financials; BY29 goal set for top quartile; Investor Day update on December 10, 2026.
• Stakeholder Communication: Reiteration that the company is "ahead" of the Investor Day waterfall targets laid out previously, with a detailed update to be provided next month.